Related references
Note: Only part of the references are listed.Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis
Candid Villanueva et al.
JOURNAL OF HEPATOLOGY (2022)
An introduction to inverse probability of treatment weighting in observational research
Nicholas C. Chesnaye et al.
CLINICAL KIDNEY JOURNAL (2022)
Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection
Roula Sasso et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Beta-blockers in cirrhosis: Evidence-based indications and limitations
Susana G. Rodrigues et al.
JHEP REPORTS (2020)
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial
Candid Villanueva et al.
LANCET (2019)
Nonselective β-Blockers Do Not Affect Mortality in Cirrhosis Patients With Ascites: Post Hoc Analysis of Three Randomized Controlled Trials With 1198 Patients
Lars Bossen et al.
HEPATOLOGY (2016)
Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure
Rajeshwar P. Mookerjee et al.
JOURNAL OF HEPATOLOGY (2016)
Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients
Peter Jepsen et al.
JOURNAL OF HEPATOLOGY (2015)
The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis
Manuela Merli et al.
LIVER INTERNATIONAL (2015)
Ascites and spontaneous bacterial peritonitis: Recommendations from two United States Centers
Vinay Sundaram et al.
SAUDI JOURNAL OF GASTROENTEROLOGY (2014)
Targeting the Gut-Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers
Bjorn S. Madsen et al.
ADVANCES IN THERAPY (2013)
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis
Thomas Reiberger et al.
JOURNAL OF HEPATOLOGY (2013)
Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience
Sara Heeboll et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2013)
Altered intestinal tight junctions' expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability
Stelios F. Assimakopoulos et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2012)
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity
Florence Wong et al.
GUT (2012)
Infections in Patients With Cirrhosis Increase Mortality Four-Fold and Should Be Used in Determining Prognosis
Vasiliki Arvaniti et al.
GASTROENTEROLOGY (2010)
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
MM Levy et al.
CRITICAL CARE MEDICINE (2003)
Estimation of integrated transition hazards and stage occupation probabilities for non-Markov systems under dependent censoring
S Datta et al.
BIOMETRICS (2002)
Share Paper
